ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Session » Pediatric Rheumatology – Clinical Poster I: Lupus, Sjögren’s Disease, and Myositis

Date: Sunday, October 21, 2018

Time: 9:00AM-11:00AM

Meeting: 2018 ACR/ARHP Annual Meeting

9:00AM-11:00AM
Abstract Number: 476
A Better Understanding of Childhood Sjögren Syndrome: Evaluation of the 2016 Acr/EULAR Classification Criteria for Use in Diagnosing Sjögren Syndrome in Children
9:00AM-11:00AM
Abstract Number: 473
A Weighty Diagnosis: Weight Change and Risk Factors in Early Juvenile Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 475
Adolescents’ Perspectives on Living with Childhood-Onset Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 480
Analyze Myositis with Ultrasound and Exercise (AMUSE) Kids- Initial Analysis of Longitudinal Data
9:00AM-11:00AM
Abstract Number: 468
Baseline Features and Outcomes of Pediatric-Onset Discoid Lupus Erythematosus: Interim Data Analysis of a Multicenter Retrospective Cohort Study
9:00AM-11:00AM
Abstract Number: 469
Clinical Characteristics and Treatment of 25 Children with Systemic Lupus Erythematosus Complicated with Thrombotic Microangiopathy in China
9:00AM-11:00AM
Abstract Number: 471
Early Signs of Diastolic Impairment in Children with Incident Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 477
Early Treatment with Intravenous Pulse Methylprednisolone or Methotrexate Is Associated with Decreased Medication Requirements at 12 and 24 Months in Patients with Juvenile Dermatomyositis: A Propensity Score Analysis
9:00AM-11:00AM
Abstract Number: 478
Evidence Based Recommendations for Corticosteroid Tapering/Discontinuation in New Onset Juvenile Dermatomyositis Patients: Results from the Paediatric Rheumatology International Trials Organisation
9:00AM-11:00AM
Abstract Number: 460
Immunomodulatory Medication Use for Youth with Newly-Diagnosed Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 466
Improving Pneumococcal Vaccination Rates in Childhood-Onset SLE Patients at a Large Tertiary Care Center: The Path to Creating a More Sustainable Model of Vaccination with the Help of EMR
9:00AM-11:00AM
Abstract Number: 479
Intravenous Immunoglobulin in Combination with Intravenous Methylprednisolone in the Treatment of Calcinosis Associated with Juvenile Dermatomyositis (JDM)
9:00AM-11:00AM
Abstract Number: 472
Libman Sacks Endocarditis in Pediatric Systemic Lupus Erythematosus: Clinical Features and Complications
9:00AM-11:00AM
Abstract Number: 474
Lupus Impact Tracker (LIT) As a New Tool in Assessing Patient Reported Outcome in Pediatric Lupus
9:00AM-11:00AM
Abstract Number: 461
Ofatumumab Use in Childhood-Onset Systemic Lupus Erythematosus: A Single-Center Experience
9:00AM-11:00AM
Abstract Number: 463
Percentage of Glomerular Crescents Predicts Renal Outcomes in Childhood-Onset Lupus Nephritis
9:00AM-11:00AM
Abstract Number: 470
Pro-Inflammatory High Density Lipoprotein Function Is Associated with Accelerated Carotid Intimal Medial Thickness Progression in Childhood-Onset SLE
9:00AM-11:00AM
Abstract Number: 459
Readmission Rate within 30 Days of Hospitalization Due to New Onset Lupus Nephritis and Associated Risk Factors: The Importance of Intravenous Pulse Methylprednisolone Therapy
9:00AM-11:00AM
Abstract Number: 465
Seasonal Variation in Cutaneous Flares for Pediatric Lupus
9:00AM-11:00AM
Abstract Number: 481
Stepping It up: The Use of Physical Activity Monitors As an Outcome Measure in Juvenile Myositis
9:00AM-11:00AM
Abstract Number: 462
Steroid Use in Pediatric Proliferative Lupus Nephritis
9:00AM-11:00AM
Abstract Number: 482
The Association of Short-Term Ultraviolet Radiation Exposure and Calcinosis in Juvenile Dermatomyositis in the Childhood Arthritis & Rheumatology Research Alliance Registry
9:00AM-11:00AM
Abstract Number: 464
The Long Term Outcomes in Chinese Children Diagnosed with Systemic Lupus Erythematosus and Biopsy Proven Lupus Nephritis – a 18-Year Cohort
9:00AM-11:00AM
Abstract Number: 467
The Prevalence and Clinical Features of Co-Occurring Autoimmunity in Children with Systemic Lupus Erythematosus: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) Legacy Registry
9:00AM-11:00AM
Abstract Number: 458
Validation of the 2012 Systemic Lupus International Collaborating Clinics (SLICC) Classification Criteria Compared to the 1997 Acr Criteria and 2017 Candidate Weighted Criteria for Lupus in Pediatric Patients

« View all sessions from this meeting

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology